← Leaderboards
Kent Lai
University Of Miami School Of Medicine
$4,516,081
Attributed
$5,673,461
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $912.3K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,673,461 · 7
By mechanism
R01$4,804,732 · 4
R21$844,446 · 2
R03$24,283 · 1
Top collaborators
- Gerard Thomas Berry2 shared
- Sihem Boudina2 shared
- Eva Morava-Kozicz2 shared
- Estela Rubio-Gozalbo2 shared
Others in their field
Top investigators on “Galactose”
- John V Fahy · University Of California San Francisco$17,627,162
- Jamey Marth · Sanford Burnham Prebys Medical Discovery Institute$13,200,239
- Jan Novak · University Of Alabama At Birmingham$11,998,798
- Michael Demetriou · University Of California-Irvine$10,040,509
- Thomas A. Platts-Mills · University Of Virginia$9,385,605
- Judith L. Fridovich-Keil · Emory University$9,333,462
Research focus
GalactoseAffectClassical GalactosemiaLifeGalactose-1-PhosphateCellsDietary RestrictionDietProductionNeonatal ScreeningPreventPhenotypeBaseCessation Of LifeHepatotoxicityIn VivoEscherichia ColiGrowthSepsisHigh Throughput ScreeningIn VitroGenesInheritedInhibitor/Antagonist
Grant awards (20)
Pathobiological mechanisms of cardiac disease in PGM1-CDG$651,868
R01 · FY2025 · HL · contact PI
Optimal Window of Opportunity for Granulosa Cell Gene Therapy in Galactosemia$171,904
R21 · FY2025 · HD · contact PI
Pathobiological mechanisms of cardiac disease in PGM1-CDG$659,131
R01 · FY2024 · HL · contact PI
Optimal Window of Opportunity for Granulosa Cell Gene Therapy in Galactosemia$253,167
R21 · FY2024 · HD · contact PI
Advancing a novel experimental mRNA-based therapy for Classic Galactosemia$190,625
R21 · FY2022 · HD · contact PI
Advancing a novel experimental mRNA-based therapy for Classic Galactosemia$228,750
R21 · FY2021 · HD · contact PI
Towards Improved Therapy for Classic Galactosemia$316,438
R01 · FY2019 · HD · contact PI
Towards Improved Therapy for Classic Galactosemia$316,438
R01 · FY2018 · HD · contact PI
Towards Improved Therapy for Classic Galactosemia$314,708
R01 · FY2017 · HD · contact PI
Toward Improved Therapy for Classic Galactosemia$300,518
R01 · FY2014 · HD · contact PI
Toward Improved Therapy for Classic Galactosemia$293,408
R01 · FY2013 · HD · contact PI
Toward Improved Therapy for Classic Galactosemia$310,213
R01 · FY2012 · HD · contact PI
Innovative Therapies and Clinical Studies for Classic Galactosemia$280,348
R01 · FY2011 · HD · contact PI
Innovative Therapies and Clinical Studies for Classic Galactosemia$292,030
R01 · FY2010 · HD · contact PI
Innovative Therapies and Clinical Studies for Classic Galactosemia$294,980
R01 · FY2009 · HD · contact PI
Innovative Therapies and Clinical Studies for Classic Galactosemia$168,856
R01 · FY2009 · HD · contact PI
Innovative Therapies and Clinical Studies for Classic Galactosemia$299,880
R01 · FY2008 · HD · contact PI
Toward Improved Therapy for Classic Galactosemia$16,113
R03 · FY2008 · MH · contact PI
Toward Improved Therapy for Classic Galactosemia$8,170
R03 · FY2008 · MH · contact PI
Innovative Therapies and Clinical Studies for Classic Galactosemia$305,916
R01 · FY2007 · HD · contact PI